- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.08. | Putting SDOH Data to Work for Systems and Patients | ||
| 28.08. | The Top-Rated Suppliers of Lu-177 for Cancer Research | ||
| 28.08. | Why Cybersecurity Is Now Central to the Patient Experience | ||
| 28.08. | EVERSANA, Waltz Health Merge to Create $6B Prescription Drug Company | ||
| 28.08. | European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option | ||
| 28.08. | CDC Director Ousted After Less Than a Month on the Job | ||
| 27.08. | Bringing Clinical Data Management to the Cloud | ||
| 27.08. | How Can Hospital-at-Home Grow Outside the Nation's Biggest Health Systems? | ||
| 27.08. | The Role of RWD in Revolutionizing Clinical Trial Design | ||
| 27.08. | Duke Spinout Launches Platform to Unite Care and Clinical Research | ||
| 27.08. | Regeneron's RNA Med for Muscle Disease Meets Trial Goals; FDA Filing Planned for Next Year | ||
| 27.08. | Dreem Health Launches 3 Partnerships to Address Sleep Disorders | ||
| 26.08. | With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test | ||
| 26.08. | Healthcare Price Transparency is Not Enough | ||
| 26.08. | On-Demand Relief: What IV Therapy Company Offers the Fastest Service? | ||
| 26.08. | Evaluating the Complexities of the Digital Operating Room | ||
| 26.08. | Without Clear Strategy, CMS' $50B Rural Hospital Fund Risks Falling Short | ||
| 25.08. | Report: Member Satisfaction in MA Insurers Is Dropping Due to Lack of Trust | ||
| 25.08. | FDA Suspends Valneva Vaccine's License Following New Reports of Adverse Events | ||
| 25.08. | The Top-Rated Assistive Devices for Children With Sensory Processing Disorders | ||
| 25.08. | Supporting the Whole Patient: The Psychological Value of Scalp Cooling in Breast Cancer Treatment | ||
| 25.08. | Regulatory Shift Paves Way for AI-Driven Heart Disease Diagnosis | ||
| 25.08. | The Critical Link: How Supporting Nurse Managers Can Help Nurses - And Improve Healthcare | ||
| 25.08. | First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen? | ||
| 25.08. | Insurers are Pulling Back on MA. How Does this Affect Patients? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .